News

Elizabeth Hastie, MD discussed the LATITUDE trial results, highlighting the need for wider access to this treatment, especially for those not virally suppressed, and could help shape future healthcare guidelines.

The individuals are agricultural workers in Washington state who were in close proximity to and working with infected poultry at an egg farm.

Study results show that the vaccine elicits a comparable immune response in high-risk adults aged 18-59 with chronic medical conditions, suggesting potential for broader vaccination efforts.

With the approval of newer products, clinicians have tools to prevent the respiratory virus in the most vulnerable population. Helen Chu, MD, MPH, offers some insights on their efficacy and the nuances of the delivery of the 2 immunizations.

The late-breaking ID Week session reported on the once-weekly oral regimen being studied for use in people with HIV who are virologically suppressed.

Evelyn Wu, MD, reveals a rise in tick-borne diseases in New Jersey over the past two decades and correlations with the influence of warming climate conditions.

Cornelius Clancy, MD, highlights the real-world outcomes of cefiderocol treatment for serious gram-negative bacterial infections, reporting a clinical success rate of 75% along with encouraging safety data.

At ID Week 2024, in a late-breaking presentation, investigators are reporting it is safe to cut the antibiotic regimen in half without endangering patients for these infections.

In our latest roundtable series, experts highlighted research showing that even mild COVID can result in cognitive impairment including brain fog and IQ decline.

Peggy Lillis Foundation CEO Christian Lillis believes patients need a seat at the table so he is advocating for past patients to become ambassadors to be a voice to help shape treatment and also continue to raise awareness about the infection.

Sean N Tucker, PhD, highlighted that VXA-GI.1-NN demonstrated safety and efficacy in reducing norovirus infections, marking a potential treatment in prevention for a diverse range of demographics.

At ID Week 2024, ViiV Healthcare reports its long-acting PrEP, cabotegravir (Apretude), is more than 99% effective.

Catherine Chappell, MD, MSc, presents what we know so far, highlighting the safety and effectiveness of direct-acting antivirals, the importance of shared decision-making, and the need for patient-provider discussions to ensure informed choices about care.

At ID Week 2024, an investigator, Amanda M. Casto, MD, PhD, discusses her work on the CASCADIA study, which examined infection rates in this setting, and how it challenged assumptions that there is likely a singular carrier bringing viruses into homes.

Nabin K. Shrestha, MD, MPH, evaluates the Cleveland Clinic's Outpatient Parenteral Antimicrobial Therapy (OPAT) program, revealing its effectiveness in managing infections while highlighting challenges in monitoring and the impact of infectious disease pharmacists on patient outcomes.

Karine G. Le Roch, PhD, discussed her research on a kalihinol analog that combats drug resistance in malaria, emphasizing the need for innovative treatments in the context of climate change and rising transmission rates.

A phase 3 therapy, zoliflodacin, has shown to be noninferior in a late stage trial. The therapy's manufacturer, Innoviva Speciality Therapeutics, is presenting data at this week's ID Week. The company's CMO David Altarac, MD, offers some insights on the therapy and the timeline for filing the paperwork for prospective FDA approval.

GS-1720 could offer a weekly dosing option for individuals living with HIV, supported by a good safety profile with no serious adverse events, which has led to the initiation of a Phase 2 study.

A serious adverse event of motor neuropathy reported in September 2024 has resulted in a hold on the investigational new drug application.

At this week’s ID Week, Ferring Pharmaceuticals shares results from its outpatient study examining its treatment, Rebyota, for the prevention of recurrence.

The Hawaii Department of Health released a report detailing the alarming link between hepatitis C and premature mortality in the state.

The Gilead capsid inhibitor has been shown to have less adverse events compared to another PrEP, and the company plans to begin regulatory filings for approval before the end of this year.

It is important to recognize this organ that has multiple life-enhancing functions.

The study indicates that targeting the sympathetic nervous system could improve CDI management, as a novel multi-target mRNA vaccine was shown to protect mice from lethal doses.

The state's outbreak has reached over 100 confirmed cases among dairy herds, contributing to a national total of 300 outbreaks across 14 states.

Last year, several cases were identified in American patients traveling to Mexico to receive cosmetic surgery. The source of transmission was discovered, and one of the investigators, Sarah Bergbower DCLS, MS, MLS (ASCP)CM, discusses her part with 1 of the cases.

The Xpert HCV assay facilitates rapid HCV diagnosis in nonclinical settings, aiding high-risk populations like those under community supervision.

This week, recent investigations link contaminated ice machines to Burkholderia multivorans infections, the hepatitis treatment market is projected to grow to USD 30.2 billion by 2032, 2020 guidelines recommend targeting specific AUC levels for optimizing vancomycin therapy, and more

In our latest roundtable series, the discussion addressed Long COVID prevalence, underreporting, accurate diagnosis, and emphasized that Long COVID serves as an umbrella term.

A NIH-funded study focused on analyzing the Wuhan strain in unvaccinated patients with COVID-19. Results showed those with certain blood types seemed to fare worse significantly increasing their risk for cardiovascular events and mortality.